Be brave and snap up Clinigen while its shares are weak
Recent share price weakness in speciality pharma firm Clinigen (CLIN:AIM) presents an attractive entry point for a business expected to deliver significant profit growth in the coming years.Stockbroker N+1 Singer forecasts it will...
11 October 2018